Optiscan Imaging Limited Announces Partnership with Prolucid Technologies to Develop AI Algorithms
algorithm to clinicians for immediate decision-making during clinical workflows. The application will be used by trained healthcare professionals in a variety of hospital and clinical settings, with a focus on oral imaging and cancer detection in the first instance. The partnership with the Ontario-based software developer has been established to further enhance the clinical capability of Optiscan's technology, with the goal of developing a Software as a Medical Device (SaMD) application that will support image collection, processing, and tissue analytics to detect the presence of pre- cancerous and cancerous cells.